UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Annals of oncology, ISSN 0923-7534, 08/2016, Volume 27, Issue 8, pp. 1525 - 1531
clinical trial | triple-negative breast cancer | pooled analysis | metastatic breast cancer | eribulin | survival | Clinical trial | Metastatic breast cancer | Eribulin | Pooled analysis | Survival | Triple-negative breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Anthracyclines - adverse effects | Adjuvants, Pharmaceutic | Receptor, ErbB-2 - genetics | Humans | Antineoplastic Agents - therapeutic use | Furans - adverse effects | Triple Negative Breast Neoplasms - drug therapy | Furans - therapeutic use | Randomized Controlled Trials as Topic | Disease-Free Survival | Taxoids - administration & dosage | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Triple Negative Breast Neoplasms - genetics | Antineoplastic Agents - adverse effects | Triple Negative Breast Neoplasms - pathology | Bridged-Ring Compounds - adverse effects | Female | Ketones - therapeutic use | Receptor, ErbB-2 - antagonists & inhibitors | Anthracyclines - therapeutic use | Bridged-Ring Compounds - administration & dosage | Ketones - adverse effects | Taxoids - adverse effects | Index Medicus | Original
Journal Article
Annals of oncology, ISSN 0923-7534, 12/2018, Volume 29, Issue 12, pp. 2341 - 2347
Neoadjuvant chemotherapy | Carboplatin | Homologuous recombinant deficiency | Survival | Triple-negative breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Doxorubicin - therapeutic use | Paclitaxel - pharmacology | Prognosis | Taxoids - pharmacology | Follow-Up Studies | Breast - surgery | Humans | Middle Aged | Polyethylene Glycols - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Taxoids - therapeutic use | Carboplatin - therapeutic use | Anthracyclines - pharmacology | Bridged-Ring Compounds - pharmacology | Doxorubicin - analogs & derivatives | Triple Negative Breast Neoplasms - pathology | Mastectomy | Female | Breast - pathology | Polyethylene Glycols - pharmacology | Bridged-Ring Compounds - therapeutic use | Recombinational DNA Repair - genetics | Triple Negative Breast Neoplasms - mortality | Paclitaxel - therapeutic use | Triple Negative Breast Neoplasms - therapy | BRCA1 Protein - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Triple Negative Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - methods | Survival Analysis | Anthracyclines - therapeutic use | Mutation | Carboplatin - pharmacology | BRCA2 Protein - genetics | Doxorubicin - pharmacology | Index Medicus
Journal Article
Oncogene, ISSN 0950-9232, 10/2020, Volume 39, Issue 42, pp. 6589 - 6605
Biochemistry & Molecular Biology | Oncology | Genetics & Heredity | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Anilides - therapeutic use | Pyrazoles - therapeutic use | Alternative Splicing | Zinc Finger Protein GLI1 - metabolism | Neoplastic Stem Cells - drug effects | Humans | Receptor, ErbB-2 - metabolism | Drug Resistance, Neoplasm | Smoothened Receptor - metabolism | Triple Negative Breast Neoplasms - drug therapy | Biphenyl Compounds - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Biphenyl Compounds - pharmacology | Neoplasm Metastasis - drug therapy | Janus Kinase 2 - metabolism | Bridged-Ring Compounds - pharmacology | Triple Negative Breast Neoplasms - pathology | Neoplastic Stem Cells - pathology | Female | Trastuzumab - pharmacology | Smoothened Receptor - antagonists & inhibitors | Janus Kinase 2 - antagonists & inhibitors | STAT3 Transcription Factor - metabolism | Pyrazoles - pharmacology | Pyridines - therapeutic use | Bridged-Ring Compounds - therapeutic use | Trastuzumab - therapeutic use | Zinc Finger Protein GLI1 - genetics | Pyrimidines - pharmacology | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Anilides - pharmacology | Cell Line, Tumor | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Antimitotic agents | Prognosis | Growth | Stem cells | Breast cancer | Metastasis | Antineoplastic agents | Vascular endothelial growth factor | Toxicity | Lung cancer | Stat3 protein | Stem cell transplantation | Cancer therapies | ErbB-2 protein | Metastases | Medical prognosis | Janus kinase 2 | Xenografts | Trastuzumab | Tumors | Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 08/2013, Volume 24, Issue 8, pp. 1972 - 1979
treatment | pancreatic | cancer | second-line | analysis | review | Second-line | Treatment | Review | Analysis | Pancreatic | Cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Gastroenterology. Liver. Pancreas. Abdomen | Liver. Biliary tract. Portal circulation. Exocrine pancreas | Pharmacology. Drug treatments | Biological and medical sciences | Multiple tumors. Solid tumors. Tumors in childhood (general aspects) | Medical sciences | Antineoplastic agents | Tumors | Erlotinib Hydrochloride | Bridged-Ring Compounds - therapeutic use | Humans | Survival | Pancreatic Neoplasms - drug therapy | Platinum Compounds - therapeutic use | Disease-Free Survival | Fluorouracil - therapeutic use | Taxoids - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Deoxycytidine - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Pancreatic Neoplasms - mortality | Deoxycytidine - analogs & derivatives | Index Medicus | Reviews
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 640 - 653
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Follow-Up Studies | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Male | Stomach Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Aged, 80 and over | Adult | Female | Stomach Neoplasms - chemistry | Adenocarcinoma - chemistry | Taxoids - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Bridged-Ring Compounds - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Stomach Neoplasms - drug therapy | Maytansine - therapeutic use | Adenocarcinoma - drug therapy | Adenocarcinoma - secondary | Esophagogastric Junction | Gastrointestinal Hemorrhage - chemically induced | Retreatment | Intention to Treat Analysis | Bridged-Ring Compounds - adverse effects | Aged | Receptor, ErbB-2 - analysis | Trastuzumab | Adenocarcinoma | Medical research | Chemotherapy | Clinical trials | Medicine, Experimental | Metastasis | Esophageal cancer | Cancer | Analysis | Index Medicus
Journal Article
Dermatologic surgery, ISSN 1076-0512, 09/2014, Volume 40, Issue 9, pp. 948 - 963
Life Sciences & Biomedicine | Dermatology | Surgery | Science & Technology | Skin Neoplasms - drug therapy | Dacarbazine - therapeutic use | Interleukin-2 - adverse effects | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Interleukin-2 - therapeutic use | Oximes - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Platinum Compounds - therapeutic use | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Dacarbazine - analogs & derivatives | Imidazoles - therapeutic use | Skin Neoplasms - pathology | Bridged-Ring Compounds - therapeutic use | Pyrimidinones - therapeutic use | Interferon-alpha - therapeutic use | Antineoplastic Agents - economics | Melanoma - secondary | Animals | Sulfonamides - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Indoles - therapeutic use | Interferon-alpha - adverse effects | Pyridones - therapeutic use | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 15, pp. 1556 - 1568
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Bridged-Ring Compounds - therapeutic use | Physicians | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Antibiotics, Antineoplastic | Capecitabine - therapeutic use | Breast Neoplasms - drug therapy | Polyethylene Glycols - therapeutic use | Taxoids - therapeutic use | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Anthracyclines - therapeutic use | Neoplasm Staging | Medical colleges | Care and treatment | Anthracyclines | Breast cancer | Product development | Metabolites | Index Medicus
Journal Article
Biochemical pharmacology, ISSN 0006-2952, 09/2012, Volume 84, Issue 6, pp. 830 - 837
Obesity | Lipid accumulation | Insulin resistance | Fatty liver | Drug discovery | Phenotypic screening | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Glucose Intolerance - metabolism | Quinolizines - therapeutic use | Drugs, Chinese Herbal - pharmacology | Male | Anti-Obesity Agents - therapeutic use | Glucose Intolerance - drug therapy | Bridged-Ring Compounds - chemistry | Bridged-Ring Compounds - pharmacology | Dietary Fats - administration & dosage | Drugs, Chinese Herbal - therapeutic use | Hypoglycemic Agents - therapeutic use | Cell Line | Drug Evaluation, Preclinical - methods | Bridged-Ring Compounds - therapeutic use | Adiposity - drug effects | Alkaloids - pharmacology | Fatty Liver - metabolism | Mice, Inbred C57BL | Insulin Resistance | Hypoglycemic Agents - chemistry | Quinolizines - pharmacology | 3T3-L1 Cells | Fatty Liver - drug therapy | Hypoglycemic Agents - pharmacology | Triglycerides - metabolism | Anti-Obesity Agents - chemistry | Animals | High-Throughput Screening Assays | Drugs, Chinese Herbal - chemistry | Lipid Metabolism - drug effects | Alkaloids - therapeutic use | Mice | Anti-Obesity Agents - pharmacology | Alkaloids - chemistry | Fructose - administration & dosage | Quinolizines - chemistry | Type 2 diabetes | Synthesis | Hydroxides | Blood sugar monitoring | Triglycerides | Medicine, Chinese | Glucose | Fatty acids | Glucose tolerance tests | Dextrose | Index Medicus
Journal Article
Seminars in oncology, ISSN 0093-7754, 10/2002, Volume 29, Issue 5, pp. 427 - 445
Life Sciences & Biomedicine | Oncology | Science & Technology | Cytokines - therapeutic use | Bridged-Ring Compounds - therapeutic use | Immunotherapy - methods | Nitrosourea Compounds - therapeutic use | Dacarbazine - therapeutic use | Humans | Interferon-alpha - therapeutic use | Interleukin-2 - therapeutic use | Organophosphorus Compounds - therapeutic use | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Paclitaxel - therapeutic use | Melanoma - secondary | Carboplatin - therapeutic use | Cisplatin - therapeutic use | Taxoids | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Tamoxifen - therapeutic use | Thalidomide - therapeutic use | Genetic Therapy - methods
Journal Article